In another Chinese newco out-licensing deal, Innocare Pharma Ltd. and Keymed Biosciences Co. Ltd. out-licensed their co-developed CD20×CD3 bispecific antibody (ICP-B02/CM355) to startup Prolium ...

Following Nobel Prize-winning chemist David Baker’s recipe for cooking an antidote to cobra venom using artificial intelligence (AI) could be faster and more effective than currently available methods ...

The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes ...

The Feinstein Institutes for Medical Research has been awarded a 5-year, $2.9 million grant from the National Institutes of Health (NIH) to investigate the potential of human ghrelin as a medical ...

Researchers from Tel Aviv Sourasky Medical Center presented data from a study that aimed to investigate the genetic mechanisms underlying yellow nail syndrome (YNS), a rare disorder characterized by ...

A recent study by researchers at the University of Florence and collaborators has demonstrated the efficacy of MRS-3997, a dual adenosine A2A/A2B receptor agonist, in reducing brain damage and ...

City of Hope conducted RNAseq analysis of patient samples with B-cell acute lymphoblastic leukemia (B-ALL), which revealed that among the m6A machinery genes, YTHDF2, which encodes YTH ...

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has synthesized kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Universitat de Barcelona has identified histone-lysine N-methyltransferase EHMT2 (H3-K9-HMTase 3; G9a) inhibitors reported to be useful for the treatment of Alzheimer’s disease among others.

Researchers from the National Health Research Institutes of Taiwan described the efficacy of BPR1J481, a multitarget tyrosine kinase inhibitor in PDX-derived colorectal cancer cells, which retain the ...

Malaria remains a significant global health challenge, causing over 600,000 deaths annually despite existing prevention and treatment measures. Current vaccines and monoclonal antibodies (mAbs) ...

Nanjing Reju Therapeutics Inc. has described tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) inhibitors reported to be useful for the treatment of inflammatory-related ...